Diabetes drug tirzepatide tested for type 1 in new trial

NCT ID NCT06820281

Recruiting now Disease control Sponsor: Victor Chang Cardiac Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests whether tirzepatide, a drug used for type 2 diabetes, can help people with type 1 diabetes. Researchers will measure how the body responds to insulin and meals before and after 6 weeks of treatment. 44 adults with type 1 diabetes who use an automated insulin pump will receive either tirzepatide or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirzepatide
What this could lead to: If it works, this could point toward a new way to manage blood sugar and reduce hypoglycemia risk in type 1 diabetes.
What could go wrong: This is a small, early-phase trial with only 44 participants. The drug may not improve insulin sensitivity or could cause side effects like nausea or hypoglycemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease diabetes mellitus endocrine system disorder glucose metabolism disease Insulin Resistance metabolic disease overnutrition type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

Victor Chang Cardiac Research Institute
RECRUITING

Sydney, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.